Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
ACTL7B Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
23 July 2026
A visual target evaluation report for ACTL7B, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ACTL7A Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
23 July 2026
A visual target evaluation report for ACTL7A, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ACTL6B Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
23 July 2026
A visual target evaluation report for ACTL6B, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ACTL6A Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
23 July 2026
A visual target evaluation report for ACTL6A, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ACTG2 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
23 July 2026
A visual target evaluation report for ACTG2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Medium-chain acyl-CoA dehydrogenase deficiency Indication Strategy Report 2026: ACADM, Trials and Deals
23 July 2026
2026 Medium-chain acyl-CoA dehydrogenase deficiency strategy: epidemiology, ACADM biology, clinical competition, recent deals, unmet need and market attractiveness.
8 min read
ACTG1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
23 July 2026
A visual target evaluation report for ACTG1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ACTC1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
23 July 2026
A visual target evaluation report for ACTC1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ACTBL2 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
23 July 2026
A visual target evaluation report for ACTBL2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ACTB Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
23 July 2026
A visual target evaluation report for ACTB, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ACTA2 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
23 July 2026
A visual target evaluation report for ACTA2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ACTA1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
23 July 2026
A visual target evaluation report for ACTA1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.